English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

The in vitro activity of BMS-207147 against 80 clinical isolates ofAspergillus was compared with that of itraconazole and amphotericin B, using a validated microtiter method. Geometric mean MICs (in μg/ml) were as follows: 1.71 for BMS-207147, 0.67 for itraconazole, and 0.63 for amphotericin B. The range of concentrations of each drug was 0.125 to &gt;16 μg/ml.Aspergillus fumigatus was significantly more susceptible to BMS-207147 (P  &lt; 0.05) thanA. terreus andA. flavus . No BMS-207147-resistantA. fumigatus isolates were identified, though eight itraconazole-resistant (MIC, &gt;8 μg/ml) isolates were. BMS-207147 is active againstAspergillus spp. at slightly high concentrations compared with itraconazole and amphotericin B.

In Vitro Activity of the New Triazole BMS-207147 against Aspergillus Species in Comparison with Itraconazole and Amphotericin B